(AALs) Acoustically active lipospheres and ultrasound are under development to deliver bioactive molecules to the vascular endothelium. The AALs are similar to both ultrasound contrast agents and drug-delivering liposomes. They can carry bioactive substances using biologically inert shells and deliver those substances when disrupted by ultrasound.
The lipospheres consist of a small gas microbubble surrounded by a thick oil shell and are enclosed by an outermost lipid layer. The gas bubble contained in these vehicles makes them acoustically active, similar to ultrasound contrast agents. Acoustically active lipospheres can be nondestructively deflected using ultrasound radiation force, and fragmented with high intensity ultrasound pulses. Their lipid-oil complex can carry bioactive substances at high concentrations. An optimized sequence of ultrasound pulses can deflect the AALs toward a vessel wall then disrupt them, painting their contents across the vascular endothelium.

See also Filling Gas, and MRX 115.

Albunex and Infoson, used mainly in cardiac evaluations, are first generation one-pass-only contrast agents and have been replaced by the new-generation contrast media. Albunex and Infoson are the same sonicated human serum albumin microbubbles. Infoson is licensed and manufactured in Europe, while Albunex was produced in the USA.
Albunex, an air-filled microbubble with a denatured albumin shell (modified from air-filled albumin microspheres prepared from sonicated 5% human serum albumin), was the first FDA-approved contrast agent, but is no longer in production.
Cardiac shunts and valve regurgitations are often evaluated with Color Doppler Imaging (CDI), which also improved with injections of Albunex, but this agent is pressure-sensitive and does not recirculate. It is effectively a one-pass-only agent, limiting its clinical efficacy.

See also First generation USCA, Echocardiography and Contrast Enhanced Ultrasound.

Myomap is an investigational ultrasound contrast agent for assessment of myocardial perfusion and has been tested in animals to determine infarct volumes in cases of coronary artery occlusion. The deposit microbubbles of Myomap consist of air filled human serum albumin microcapsule with a thick and rigid shell.

Quantison, consisting of air-filled microbubbles with stiff and rigid human serum albumin shells, is an investigational ultrasound contrast agent for the assessment of coronary artery disease.
The stiff shell inhibits the bubbles from oscillating and decrease non-linear scattering. Quantison is capable of long lasting cavity contrast and myocardial opacification using intermittent imaging.

SonoGen (QW7437) is an anionically charged 2% perfluorocarbon emulsion under development as a transpulmonary myocardial ultrasound contrast agent (UCA). The SonoGen microbubbles have a reduced adherence to the negatively charged vascular endothelium and reduced coalescence. SonoGen, a second generation USCA has the theoretical potential to provide high safety and efficacy and improved tissue grayscale persistence compared to first generation fluorocarbon contrast agents.